COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
Yotam Bronstein,Roi Gat,S Levi,Yael C Cohen,Efrat Luttwak,Noam Benyamini,Tamir Shragai,Roy Vitkon,Miriam Neaman,Nili Eilaty,Mor Levi,Svetlana Trestman,Chava Perry,Yair Herishanu,Irit Avivi +14 more
TLDR
Christensen et al. as discussed by the authors reported the clinical outcome of 131 hematologic patients with lymphoproliferative diseases, infected with SARS-CoV-2 during the Omicron surge in Israel, between January and March 2022.About:
This article is published in Cancer Cell.The article was published on 2022-04-01 and is currently open access. It has received 9 citations till now. The article focuses on the topics: Medicine & Surge.read more
Citations
More filters
Journal ArticleDOI
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak
Milena Kohn,Tamim Alsuliman,Sylvain Lamure,Morgane Cheminant,Jeremy Delage,Corinne Merle De Boever,Jean-Jacques Tudesq,Zora Marjanovic,Zoé Van de Wyngaert,Florent Malard,Eolia Brissot,Sophie Rigaudeau,Stéphanie Marque-Juillet,Audrey Therby,Guillaume Cartron,Philippe Rousselot,Olivier Hermine,Remy Dulery,Caroline Besson +18 more
TL;DR: Kohn et al. as discussed by the authors proposed a service d'h ematologie for clinical Hematology at the Centre Hospitalier de Versailles, Le Chesnay, France.
Journal ArticleDOI
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
Michele Merli,Isacco Ferrarini,Francesco Merli,Alessandro Busca,Roberto Mina,Brunangelo Falini,Riccardo Bruna,Roberto Cairoli,Monia Marchetti,A. Romano,Michele Cavo,Luca Arcaini,Livio Trentin,Chiara Cattaneo,Enrico Derenzini,Nicola Stefano Fracchiolla,Francesco Marchesi,Anna Maria Scattolin,Atto Billio,Monica Bocchia,Massimo Massaia,Carlo Gambacorti-Passerini,Francesca Romana Mauro,Massimo Gentile,Sara F. Mohamed,Matteo G. Della Porta,Elisa Coviello,Daniela Cilloni,Giuseppe Visani,Augusto B. Federici,Maria Chiara Tisi,Laura Cudillo,Sara Galimberti,Filippo Gherlinzoni,Livio Pagano,Anna Guidetti,Lorenza Bertù,Paolo Corradini,Francesco Passamonti,Carlo Visco +39 more
TL;DR: A dismal COVID-related outcome in a significant fraction of CLL patients is reported, that can be nicely predicted by clinical parameters, and is independently associated with poor survival.
Journal ArticleDOI
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study
Alessandra Oliva,Francesco Cogliati Dezza,Flavia Petrucci,Francesco Romani,Matteo Morviducci,Flavio Marco Mirabelli,F. Cancelli,Emanuele Valeriani,Giulia Marcelli,Francesco Pugliese,Ombretta Turriziani,Paolo Ricci,Mario Venditti,Paolo Palange,Claudio Maria Mastroianni +14 more
TL;DR: In this paper , the authors investigated whether vaccination and monoclonal antibodies (mAbs) have modified the outcomes of haematological malignancies (HM) patients with COVID-19.
Journal ArticleDOI
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study
Francesca Romana Mauro,Diana Giannarelli,Clementina Maria Galluzzo,Andrea Visentin,Anna Maria Frustaci,Paolo Sportoletti,Candida Vitale,Gianluigi Reda,Massimo Gentile,Luciano Levato,Roberta Murru,Daniele Armiento,M. C. Molinari,Giulia Proietti,Sara Pepe,Filomena De Falco,Veronica Mattiello,L. Barabino,Roberta Amici,Marta Coscia,Alessandra Tedeschi,Corrado Girmenia,Livio Trentin,Silvia Baroncelli +23 more
TL;DR: In this article , the authors evaluated COVID-19 morbidity and severity in 200 consecutive patients with chronic lymphocytic leukemia (CLL) after the SARS-CoV-2 vaccine.
Posted ContentDOI
Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study
TL;DR: In this paper , the authors investigated whether vaccination and monoclonal antibodies (mAbs) have modified the outcomes of hematological malignancies (HM) patients with COVID-19.
References
More filters
Journal ArticleDOI
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
TL;DR: In this paper , the relative risk of hospital attendance or admission within 14 days, or death within 28 days after confirmed infection, was estimated using proportional hazards regression, with higher reductions for more severe endpoints and significant variation with age.
Journal ArticleDOI
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Tommy Nyberg,Neil M. Ferguson,Seth Flaxman,Wes Hinsley,Meaghan Kall,Paula Blomquist,N. A. Aziz,Kattie Harman,Sebastian Funk,Meera Chand,Azra C. Ghani,Shaun R. Seaman,Daniela De Angelis,S. Nash,H. Webster,Nick Andrews,Jamie Lopez Bernal,Samir Bhatt,Asad Zaidi,Erik M. Volz,Nur Adilah Abdul Aziz,Sam Abbott,Russell Hope,Andre Charlett,Gavin Dabrera,Anne M. Presanis,Simon Thelwall +26 more
TL;DR: The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for omicron than for delta, with higher reductions for more severe endpoints and significant variation with age.
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Yair Herishanu,Irit Avivi,Anat Amit Aharon,Gabi Shefer,Shai Levi,Yotam Bronstein,Miguel Morales,Tomer Ziv,Yamit Shorer Arbel,Lydia Scarfò,Erel Joffe,Chava Perry,Paolo Ghia +12 more
TL;DR: In this article, the authors evaluated humoral immune responses to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects.
Journal ArticleDOI
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients.
Abi Vijenthira,Inna Y. Gong,Thomas Andrew Fox,Stephen Booth,Gordon Cook,Bruno Fattizzo,Fernando Martín-Moro,Jerome Razanamahery,John Riches,Jeffrey I. Zwicker,Rushad Patell,Marie-Christiane Mb Vekemans,Lydia Scarfò,Thomas Chatzikonstantinou,Halil Yildiz,Raphaël Lattenist,Ioannis Mantzaris,William A. Wood,Lisa K. Hicks,Lisa K. Hicks +19 more
TL;DR: Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying and adults aged ≥60 years have significantly higher mortality; pediatric patients appear to be relatively spared.
Journal ArticleDOI
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Anthony R. Mato,Lindsey E. Roeker,Nicole Lamanna,John N. Allan,Lori A. Leslie,John M. Pagel,Krish Patel,Anders Österborg,Daniel Wojenski,Manali Kamdar,Scott F. Huntington,Matthew S. Davids,Jennifer R. Brown,Darko Antic,Ryan Jacobs,Inhye E. Ahn,Jeffrey Pu,Krista Isaac,Paul M. Barr,Chaitra S. Ujjani,Mark B. Geyer,Ellin Berman,Andrew D. Zelenetz,Nikita Malakhov,Richard R. Furman,Michael Koropsak,Neil Bailey,Lotta Hanson,Guilherme Fleury Perini,Shuo Ma,Christine E. Ryan,Adrian Wiestner,Craig A. Portell,Mazyar Shadman,Elise A. Chong,Danielle M. Brander,Suchitra Sundaram,Amanda N. Seddon,Erlene K. Seymour,Meera Patel,Nicolas Martinez-Calle,Talha Munir,Renata Walewska,Angus Broom,Harriet S. Walter,Dima El-Sharkawi,Helen Parry,Matthew R. Wilson,Piers E.M. Patten,Jose Angel Hernandez-Rivas,Fatima Miras,Noemi Fernandez Escalada,Paola Ghione,Chadi Nabhan,Sonia Lebowitz,Erica Bhavsar,Javier López-Jiménez,Daniel Naya,José A. García-Marco,Sigrid S. Skånland,Raul Cordoba,Toby A. Eyre +61 more
TL;DR: The data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death.